<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <!--The publisher of this article does not allow downloading of the full text in XML form.-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Haematologica</journal-id>
      <journal-id journal-id-type="iso-abbrev">Haematologica</journal-id>
      <journal-id journal-id-type="hwp">haematol</journal-id>
      <journal-id journal-id-type="publisher-id">Haematologica</journal-id>
      <journal-title-group>
        <journal-title>Haematologica</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0390-6078</issn>
      <issn pub-type="epub">1592-8721</issn>
      <publisher>
        <publisher-name>Ferrata Storti Foundation</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25616577</article-id>
      <article-id pub-id-type="pmc">4380721</article-id>
      <article-id pub-id-type="doi">10.3324/haematol.2014.115840</article-id>
      <article-id pub-id-type="publisher-id">1000479</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
          <subj-group subj-group-type="heading">
            <subject>Myeloproliferative Disorders</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Verstovsek</surname>
            <given-names>Srdan</given-names>
          </name>
          <xref ref-type="aff" rid="af1-1000479">1</xref>
          <xref ref-type="corresp" rid="c1-1000479"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesa</surname>
            <given-names>Ruben A.</given-names>
          </name>
          <xref ref-type="aff" rid="af2-1000479">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gotlib</surname>
            <given-names>Jason</given-names>
          </name>
          <xref ref-type="aff" rid="af3-1000479">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Levy</surname>
            <given-names>Richard S.</given-names>
          </name>
          <xref ref-type="aff" rid="af4-1000479">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <xref ref-type="aff" rid="af5-1000479">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>DiPersio</surname>
            <given-names>John F.</given-names>
          </name>
          <xref ref-type="aff" rid="af6-1000479">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Catalano</surname>
            <given-names>John V.</given-names>
          </name>
          <xref ref-type="aff" rid="af7-1000479">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Deininger</surname>
            <given-names>Michael W.N.</given-names>
          </name>
          <xref ref-type="aff" rid="af8-1000479">8</xref>
          <xref ref-type="author-notes" rid="fn1-1000479">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>Carole B.</given-names>
          </name>
          <xref ref-type="aff" rid="af9-1000479">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silver</surname>
            <given-names>Richard T.</given-names>
          </name>
          <xref ref-type="aff" rid="af10-1000479">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Talpaz</surname>
            <given-names>Moshe</given-names>
          </name>
          <xref ref-type="aff" rid="af11-1000479">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Winton</surname>
            <given-names>Elliott F.</given-names>
          </name>
          <xref ref-type="aff" rid="af12-1000479">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harvey</surname>
            <given-names>Jimmie H.</given-names>
            <suffix>Jr</suffix>
          </name>
          <xref ref-type="aff" rid="af13-1000479">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Arcasoy</surname>
            <given-names>Murat O.</given-names>
          </name>
          <xref ref-type="aff" rid="af14-1000479">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hexner</surname>
            <given-names>Elizabeth O.</given-names>
          </name>
          <xref ref-type="aff" rid="af15-1000479">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lyons</surname>
            <given-names>Roger M.</given-names>
          </name>
          <xref ref-type="aff" rid="af16-1000479">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Raza</surname>
            <given-names>Azra</given-names>
          </name>
          <xref ref-type="aff" rid="af17-1000479">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vaddi</surname>
            <given-names>Kris</given-names>
          </name>
          <xref ref-type="aff" rid="af4-1000479">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>William</given-names>
          </name>
          <xref ref-type="aff" rid="af4-1000479">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Peng</surname>
            <given-names>Wei</given-names>
          </name>
          <xref ref-type="aff" rid="af4-1000479">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sandor</surname>
            <given-names>Victor</given-names>
          </name>
          <xref ref-type="aff" rid="af4-1000479">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kantarjian</surname>
            <given-names>Hagop</given-names>
          </name>
          <xref ref-type="aff" rid="af1-1000479">1</xref>
        </contrib>
        <on-behalf-of>For the COMFORT-I investigators</on-behalf-of>
      </contrib-group>
      <aff id="af1-1000479"><label>1</label>The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
      <aff id="af2-1000479"><label>2</label>Mayo Clinic, Scottsdale, AZ, USA</aff>
      <aff id="af3-1000479"><label>3</label>Stanford Cancer Institute, Stanford, CA, USA</aff>
      <aff id="af4-1000479"><label>4</label>Incyte Corporation, Wilmington, DE, USA</aff>
      <aff id="af5-1000479"><label>5</label>Princess Margaret Cancer Center, University of Toronto, ON, Canada</aff>
      <aff id="af6-1000479"><label>6</label>Washington University School of Medicine, St. Louis, MO, USA</aff>
      <aff id="af7-1000479"><label>7</label>Frankston Hospital and Department of Clinical Haematology, Monash University, Frankston, Australia</aff>
      <aff id="af8-1000479"><label>8</label>*Oregon Health and Science University, Portland, OR, USA</aff>
      <aff id="af9-1000479"><label>9</label>Saint Agnes Cancer Institute, Baltimore, MD, USA</aff>
      <aff id="af10-1000479"><label>10</label>Weill Cornell Medical Center, New York, NY, USA</aff>
      <aff id="af11-1000479"><label>11</label>University of Michigan, Ann Arbor, MI, USA</aff>
      <aff id="af12-1000479"><label>12</label>Emory University School of Medicine, Atlanta, GA, USA</aff>
      <aff id="af13-1000479"><label>13</label>Birmingham Hematology and Oncology, Birmingham, AL, USA</aff>
      <aff id="af14-1000479"><label>14</label>Duke University Health System, Durham, NC, USA</aff>
      <aff id="af15-1000479"><label>15</label>Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA</aff>
      <aff id="af16-1000479"><label>16</label>Cancer Care Centers of South Texas/US Oncology, San Antonio, TX, USA</aff>
      <aff id="af17-1000479"><label>17</label>Columbia Presbyterian Medical Center, New York, NY, USA</aff>
      <author-notes>
        <corresp id="c1-1000479">Correspondence: <email>sverstov@mdanderson.org</email></corresp>
        <fn id="fn1-1000479">
          <label>*</label>
          <p>Currently at the Division of Hematology and Hematologic Malignancies and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2015</year>
      </pub-date>
      <volume>100</volume>
      <issue>4</issue>
      <fpage>479</fpage>
      <lpage>488</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>8</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright© Ferrata Storti Foundation</copyright-statement>
        <copyright-year>2015</copyright-year>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="100479.pdf"/>
      <abstract>
        <p>In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo in patients with intermediate-2 or high-risk myelofibrosis. This planned analysis assessed the long-term efficacy and safety of ruxolitinib at a median follow-up of 149 weeks. At data cutoff, approximately 50% of patients originally randomized to ruxolitinib remained on treatment whereas all patients originally assigned to placebo had discontinued or crossed over to ruxolitinib. At week 144, mean spleen volume reduction was 34% with ruxolitinib. Previously observed improvements in quality-of-life measures were sustained with longer-term ruxolitinib therapy. Overall survival continued to favor ruxolitinib despite the majority of placebo patients crossing over to ruxolitinib [hazard ratio 0.69 (95% confidence interval: 0.46–1.03); <italic>P</italic>=0.067]. Exploratory analyses suggest that crossover may have contributed to an underestimation of the true survival difference between the treatment groups. Ruxolitinib continued to be generally well tolerated; there was no pattern of worsening grade ≥3 anemia or thrombocytopenia with longer-term ruxolitinib exposure. These longer-term data continue to support the efficacy and safety of ruxolitinib in patients with myelofibrosis. <italic>The study is registered at <ext-link ext-link-type="uri" xlink:href="clinicaltrials.gov">clinicaltrials.gov</ext-link>: NCT00952289.</italic></p>
      </abstract>
    </article-meta>
  </front>
</article>

